ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 6.8 | 7.3 | 6.1 |
| Other income | 2.0 | 0.0 | 0.3 |
| Total income | 8.8 | 7.3 | 6.4 |
| Profit before exceptional items & tax | -2.3 | -3.1 | -8.3 |
| Profit before tax | -2.3 | -3.1 | -8.3 |
| Net profit | -2.3 | -3.1 | -8.3 |
| Operating margin | -26.1% | -42.5% | -129.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +11.50% |
|---|
BSE results filing, NSE: KREBSBIO. Figures extracted from the filing.
Krebs Biochemicals & Industries Ltd: key numbers
- Share price
- ₹61.19
- Market cap
- ₹131.9 Cr
- Revenue (annual)
- ₹23.73 Cr
- Net profit (annual)
- ₹-16.93 Cr
- P/E (TTM)
- -9.9×Sector 43.8×
- Promoter holding
- 72.74%+0.00% QoQ
- FII holding
- 0.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krebs Biochemicals & Industries Ltd
All →Krebs Biochemicals & Industries Q2 FY27 Results: Net Loss of ₹5.4 Cr, Loss Narrows
Krebs Biochemicals reported Q2 FY27 standalone results with a net loss of Rs.539.85 Cr. The half-year loss widened to Rs.788.33 Cr amid Vizag unit closure.
- Key figure
- Net loss ₹5.4 Cr
Krebs Biochemicals & Industries Board Meeting Date
Krebs Biochemicals & Industries Limited has scheduled a board meeting for October 29, 2026. The board will consider and adopt unaudited financial results for the second quarter.
Krebs Biochemicals & Industries Other Announcement
Krebs Biochemicals & Industries Ltd filed its quarterly shareholding pattern as mandated by SEBI regulations, disclosing the distribution of equity stakes among shareholders.
Krebs Biochemicals & Industries Annual General Meeting
Krebs Biochemicals & Industries Limited conducted its 34th Annual General Meeting on September 29, 2026. Shareholders considered the adoption of FY2025-26 audited financials and related party transactions.
Krebs Biochemicals & Industries Annual General Meeting
Krebs Biochemicals and Industries Limited has issued a notice for its 34th Annual General Meeting scheduled for September 29, 2026. Key agenda items include the approval of financial statements and related party transactions.
Krebs Biochemicals & Industries Annual Report
Krebs Biochemicals & Industries Limited has submitted its 34th Annual Report for the financial year 2025-26. The report includes financial highlights, directors' report, and audited financial statements.